ADHD treatment in the 1990s centered heavily on stimulant medication, particularly Ritalin (methylphenidate), which saw explosive growth in prescriptions throughout the decade. But the 90s were also a transformative period for how clinicians understood, diagnosed, and debated the condition. New diagnostic categories emerged, new medications hit the market, a landmark government study reshaped treatment guidelines, and a fierce public controversy erupted over whether too many children were being medicated.
A New Diagnostic Framework Changed Everything
The 1994 publication of the DSM-IV fundamentally changed how clinicians identified ADHD. For the first time, the disorder was split into three subtypes based on two symptom dimensions: nine symptoms of inattention and nine symptoms of hyperactivity-impulsivity. Children with six or more inattention symptoms but fewer than six hyperactivity symptoms received a Predominantly Inattentive diagnosis. Those with the reverse pattern were classified as Predominantly Hyperactive-Impulsive, a subtype that emerged unexpectedly from the DSM-IV field trials. Children meeting both thresholds were diagnosed with the Combined Type.
This mattered enormously for treatment. Before 1994, the diagnosis leaned heavily on visible hyperactivity, which meant quieter, daydreamy kids (often girls) were frequently missed. The new framework opened the door for a much broader population to receive a diagnosis and, consequently, treatment. By 1997-1998, an estimated 6.1% of children aged 4 to 17 had been diagnosed, a number that would climb steadily in the years that followed.
Ritalin Was the Default, and Its Use Surged
Methylphenidate, sold primarily as Ritalin, dominated ADHD treatment throughout the 1990s. It had been on the market since the 1950s, but the 90s saw a dramatic acceleration in use. The DEA’s production quota for methylphenidate increased every year of the decade except 1990. In 1994 alone, the quota jumped nearly 55%, from 5,300 kilograms to over 8,100 kilograms. That surge reflected both rising diagnosis rates and growing physician comfort with prescribing stimulants to children.
Ritalin in this era was an immediate-release tablet, which meant children typically needed two or three doses per day. Many kids took a dose at home before school, another at the nurse’s office around lunchtime, and sometimes a third in the afternoon. The lunchtime dose was a visible, sometimes stigmatizing ritual that became a defining image of 90s ADHD treatment. Extended-release formulations existed but were not yet the standard.
Then in 1996, the FDA approved Adderall, a mix of amphetamine salts that Richwood Pharmaceuticals had been promoting since 1994 as a “unique once a day alternative” for ADHD. Adderall’s longer duration of action meant some children could skip the midday school dose, and it quickly carved out a significant share of the market. Together, Ritalin and Adderall became the two pillars of 90s ADHD pharmacotherapy.
The Landmark MTA Study
The most influential piece of ADHD research from the decade was the Multimodal Treatment Study of Children with ADHD, known as the MTA study, published in December 1999. Funded by the National Institute of Mental Health, it was the largest and most rigorous ADHD treatment trial ever conducted at that point, and its results shaped clinical practice for years.
The study compared four approaches: carefully managed medication alone, intensive behavioral therapy alone, a combination of both, and routine community care (essentially whatever treatment families were already getting from local providers). The core finding was clear: medication management, whether alone or combined with behavioral therapy, produced the greatest improvement in ADHD symptoms. Both of those approaches significantly outperformed intensive behavioral therapy alone and routine community care, with benefits lasting at least 14 months.
The results were more nuanced than the headlines suggested, though. For problems beyond core ADHD symptoms, like anxiety, academic struggles, parent-child conflict, and social skills, combination treatment was consistently the strongest option. It outperformed routine community care across the board, while medication alone or behavioral therapy alone did not. Children in the combination group also ended up taking lower medication doses than those on medication alone. So while the study cemented medication as the front-line treatment, it also made a case that behavioral support added real value, particularly for children dealing with more than just attention and hyperactivity problems.
Behavioral Therapy and School-Based Approaches
Non-medication treatment in the 90s typically meant behavioral therapy, though its availability and quality varied widely. The behavioral interventions used in the MTA study were intensive by any standard: parent training groups, classroom-based strategies, a full summer treatment program, and individual work with children on social skills and problem-solving. Most families in community settings received something far less structured.
In schools, the late 90s brought important changes. The 1997 reauthorization of the Individuals with Disabilities Education Act helped clarify that children with ADHD could qualify for special education services under the “Other Health Impairment” category. Before this, families often struggled to secure accommodations. Section 504 plans, which provided classroom modifications like preferential seating, extended test time, and reduced homework loads, became a common pathway for students whose ADHD affected their schoolwork but who didn’t qualify for full special education services.
Elimination Diets and Alternative Treatments
Many parents in the 90s, wary of stimulant medication for young children, turned to dietary interventions. The most well-known was the Feingold diet, originally developed in the 1970s, which eliminated artificial food colorings and preservatives. By the 90s, a modified version focused specifically on synthetic colorings and preservatives, which Feingold had come to believe were the primary dietary culprits behind hyperactive behavior.
Other elimination approaches ranged from removing single suspected foods (like eggs or dairy) to far more restrictive “few foods” diets that limited children to a small number of items with low allergenic potential, such as lamb, rice, and pears. Some families tried the six-food elimination diet, which cut out the most common allergens: cow’s milk protein, soy, wheat, eggs, peanuts, and seafood. Omega-3 fatty acid supplements also gained popularity during this period, along with various multinutrient supplements. The evidence base for these approaches was thin and inconsistent, but they remained popular among parents seeking alternatives to Ritalin.
The Overdiagnosis Controversy
No account of 90s ADHD treatment is complete without the fierce public debate over whether the condition was being overdiagnosed and overmedicated. The controversy reached a flashpoint in 1995 when research documented unusually high rates of ADHD diagnosis and stimulant treatment in southeastern Virginia. Gretchen LeFever, a psychologist conducting epidemiological surveys in the region, published findings showing that ADHD diagnosis and drug treatment rates in her community were exceptionally high.
Her work drew intense backlash. Russell Barkley, one of the most prominent ADHD researchers in the country, argued that ADHD was a genetic disorder that was not being overdiagnosed or overtreated, and that in fact most children with the condition were going unmedicated when they should not have been. The two debated publicly in 2000, in a forum where LeFever was given 15 minutes to present while Barkley received 45. Barkley opened by declaring LeFever was “not a scientist” and dismissed her research entirely. Critics noted that many of his objections targeted the implications of her findings rather than her methodology.
The debate extended well beyond these two figures. In the early 2000s, an international group of mental health professionals published a consensus statement defending widespread ADHD diagnosis and medication use. Another international group responded with a pointed critique, questioning why eminent psychiatrists and psychologists would publish a statement that appeared designed to shut down legitimate scientific debate about diagnosis and treatment rates. Ties between prominent ADHD researchers and the pharmaceutical industry added fuel to public skepticism.
For parents navigating this landscape, the 90s were a confusing time. Media coverage swung between portraying Ritalin as a miracle drug and warning that an entire generation of children was being unnecessarily medicated. The reality, as the MTA study and subsequent research would show, was that medication genuinely helped many children with ADHD, but that the quality of diagnosis and follow-up care varied enormously from one community to the next.
How 90s Assessment Worked in Practice
Diagnosing ADHD in the 1990s was less standardized than it is today. Pediatricians and psychiatrists relied on a combination of clinical interviews, parent and teacher questionnaires, and sometimes computerized attention tests. Common tools included the ADHD Rating Scale, the Child Behaviour Checklist (filled out by parents), and the Conners’ Continuous Performance Test, a computer-based task that measured a child’s ability to sustain attention and inhibit impulsive responses over a boring, repetitive 14-minute session.
In practice, the thoroughness of evaluation varied dramatically. Some children received comprehensive assessments involving multiple informants, structured interviews, and psychological testing. Others were diagnosed after a single brief office visit based largely on a parent’s description of behavior. This inconsistency fueled the overdiagnosis debate and led professional organizations to push for more systematic evaluation practices by the end of the decade.